Pharma stock jumps 6% after opening new production facility worth ₹125 Cr

Pharma stocks saw a 6 percent surge following the inauguration of a state-of-the-art E-Production Block in Maharashtra, with an investment of Rs.125 crore. The new facility is expected to enhance the company’s production capabilities, contributing to its growth in the competitive pharmaceutical market. 

Price Variation 

In Wednesday’s trading session, Supriya Lifescience Ltd’s share price soared 6 percent to an intra-day high of Rs.758.50 per share, up from the previous close of Rs.717.25 apiece. The price has since retreated and is currently trading at Rs.748.90 per share. Over the past year, the shares have delivered over 170 percent returns. 

What is the news 

Supriya Lifescience Ltd (SLL) has expanded its operations with the inauguration of a new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. 

With an investment of approximately Rs.125 crore, the new facility adds 335 kiloliters of capacity, boosting the site’s overall capacity by over 55 percent, from 597 KLPD to 932 KLPD. This expansion enhances the company’s production capabilities, supporting its continued growth in the pharmaceutical sector. 

The new facility, spread across 5,000 square meters and designed over four levels, ensures efficient operations and safe workflows. It is equipped with 33 reactors, including both stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL. 

The design incorporates gravity-based process flows to improve safety, maintain product integrity, and optimize overall efficiency. 

Also read….

Management Commentary 

Dr. Satish Wagh, Executive Chairman & WTD of Supriya Lifescience Ltd, commenting on the occasion, said, “We are excited to inaugurate our new manufacturing Module E block today. With the latest technologies and our team’s dedication, we are poised to elevate product quality, ensure efficiency through backward integration, and meet growing global demand. 

Module E is a testament to our strategic focus on innovation and sustainability, serving as a key driver of growth while reducing dependence on imports. As SLL continues to strengthen its infrastructure and expand its product portfolio, the company remains dedicated to setting new benchmarks in the pharmaceutical industry and delivering value to its stakeholders.” 

Financial Overview 

Turning towards the financials of the company, Supriya Lifescience Ltd reported Q2 FY25 revenue of Rs.166 crore, up remarkably by 19 percent from Rs.140 crore in the same quarter last year. Profit After Tax (PAT) increased by 53.3 percent to Rs.46 crore, compared to Rs.24 crore in the same period.

Company Profile 

Founded in 1987 and headquartered in Mumbai, Supriya Lifescience Ltd is an Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company operates a state-of-the-art manufacturing facility in Maharashtra, which is certified by leading international regulatory authorities. 

Written by – Siddesh S Raskar 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 6% after opening new production facility worth ₹125 Cr appeared first on Trade Brains.